GlassScriptPhysician profile
Lam Q Le
NPI 1164824066
$8,842.50
in general payments reported to CMS, 2019-2025
30 companies · $2,638 in 2025
The $2,638 reported for 2025 was more than what 97% of Surgical providers received nationally (typical 2025 total: $146).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $908 · 2022: $1,180 · 2023: $1,378 · 2024: $2,739 · 2025: $2,638.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,318 · Education: $437.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,317.63 |
| Education | $436.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,518.72 | 2021-2025 | |
| Sun Pharmaceutical Industries INC. | $1,007.78 | 2021-2025 | Absorica Ld, Winlevi, Odomzo |
| Lilly USA, LLC | $981.99 | 2021-2025 | Taltz, Olumiant, Ebglyss |
| Janssen Biotech, INC. | $978.15 | 2021-2025 | Tremfya, Simponi, Simponi Aria |
| Incyte Corporation | $669.00 | 2021-2025 | Opzelura, Opzelura |
| Novartis Pharmaceuticals Corporation | $582.67 | 2021-2025 | |
| Dermavant Sciences, INC. | $494.10 | 2022-2024 | Vtama |
| Arcutis Biotherapeutics, INC. | $357.95 | 2023-2025 | Zoryve |
| Galderma Laboratories, L.P. | $343.55 | 2021-2025 | Nemluvio |
| Pfizer INC. | $325.83 | 2021-2024 | |
| E.R. Squibb & Sons, L.L.C. | $294.32 | 2022-2025 | Sotyktu |
| Ucb, INC. | $258.05 | 2022-2025 | Bimzelx, Cimzia |
| Regeneron Healthcare Solutions, INC. | $220.73 | 2021-2025 | Dupixent, Libtayo |
| Leo Pharma INC. | $165.61 | 2021-2025 | Adbry |
| Genzyme Corporation | $75.83 | 2021-2025 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $68.85 | 2022-2025 | Otezla, Otezla |
| Journey Medical Corporation | $59.48 | 2022 | |
| Fresenius Kabi USA, LLC | $57.21 | 2023-2024 | Idacio |
| Strata Skin Sciences, INC. | $46.19 | 2022-2025 | Xtrac |
| Almirall LLC | $43.11 | 2021-2025 | Klisyri |
| Organon LLC | $38.69 | 2025 | Vtama |
| Allergan, INC. | $37.98 | 2022 | |
| Epi Health, LLC | $34.31 | 2021-2022 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $34.13 | 2021 | |
| Biofrontera INC. | $32.92 | 2024-2025 | Xepi, Bf-Rhodoled, Ameluz |
| Organogenesis INC. | $29.01 | 2022-2025 | Via Matrix |
| Janssen Scientific Affairs, LLC | $25.04 | 2021 | |
| Mimedx Group, INC. | $21.59 | 2024 | |
| Helsinn Therapeutics (U.S.), INC. | $20.52 | 2025 | Valchlor |
| Verrica Pharmaceuticals INC. | $19.19 | 2025 | Ycanth |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lam Le listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.